Aurobindo receives approval for AIDS drug
22 Dec 2006
Aurobindo Pharma Ltd has received tentative approval from the US FDA for Efavirenz capsules, of 50mg, 100mg and 200mg dosages. This is Aurbindo Pharma''s 33rd generic approval from the US FDA and 18th in its ARV line.
The company says this is first generic alternative to ''Sustiva Capsules'' from Bristol Myers Squibb Co.
Efavirenz is a key ARV in the anti-AIDS therapy. Efavirenz represents a significant opportunity in Africas for the Company under PEPFAR programme.
Efavirenz is in the class of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs), which helps keep the AIDS virus from reproducing in cells. It is used in the combination with other NRTI drugs.